Clinical Trials

The aim of this study is to determine which clinical characteristics are associated with diplopia in patients with epiretinal membranes. 

The purpose of this study is to review the management and outcomes of patients who had vitreoretinal surgery at the Mayo Clinic. A search will be made using relevant ICD-9 codes and surgical databases. Presenting symptoms, visual acuity, management strategies, visual and anatomic outcomes will be reviewed.

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ...

The purpose of this study is to learn about cell function in different tissues of the eye in various ocular diseases via transcriptomics in the Mayo Clinic laboratory.

The purpose of this study is to identify persons with MacTel Type 2, and their affected family members to create a registry of persons with MacTel Type 2. This registry will be used to study participants with MacTel Type 2 now and may be used in the future to identify persons to be in a study that may help find a way to prevent or treat this eye condition. We also wish to keep in contact with persons who have been told by their MacTel doctor that they have MacTel Type 2.

The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.

The purpose of this study is to evaluate the ability of appropriately-trained family physicians to screen for and identify Diabetic Retinopathy using retinal camera and, secondarily, to describe patients’ perception of the convenience and cost-effectiveness of retinal imaging.